title: Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
abstract: BACKGROUND
  The aim of this study was to assess the efficacy and safety of targeted radionuclide therapy with [90Y-DOTA0, Tyr3]-octreotide (90Y-DOTATOC) in patients with metastatic neuroendocrine tumors.
  
  
  METHODS
  One hundred and sixteen patients with metastatic neuroendocrine tumors were included. All patients were pre-therapeutically staged with morphological imaging procedures and with somatostatin receptor scintigraphy. The scintigraphy was positive in all cases. The patients were treated with 162-200 mCi/m2 body surface. In 57 patients, the quality of life was assessed with the National Cancer Institute grading criteria (NCI-CTC). Restaging was performed 8-12 weeks after the last treatment cycle. Blood samples were drawn every 2 weeks after the treatment to evaluate toxicity.
  
  
  RESULTS
  Complete remissions were found in 4%, partial remissions in 23%, stabilization in 62% and progressive disease in 11%. A significant reduction of symptoms was found in 83%. No serious adverse event occurred and the toxicity was acceptable.
  
  
  CONCLUSIONS
  90Y-DOTATOC is a safe and effective treatment for patients with metastatic neuroendocrine tumors.
authors.affiliation: Institute of Nuclear Medicine, University Hospital Basel, Switzerland. fforrer@uhbs.ch
authors.forename: Flavio
authors.initials: F
authors.lastname: Forrer
authors.forename: Christian
authors.initials: C
authors.lastname: Waldherr
authors.forename: Helmut R
authors.initials: HR
authors.lastname: Maecke
authors.forename: Jan
authors.initials: J
authors.lastname: Mueller-Brand
mesh_terms: D006801:Humans; D007414:Intestinal Neoplasms / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000532:radiotherapy; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000532:radiotherapy; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000532:radiotherapy; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide